

A Next Generation Stem Cell Therapeutics Company

AGM Presentation: Cynata Therapeutics Limited 27 November 2019



Dr Ross Macdonald MD & CEO



Important Information

This presentation has been prepared by Cynata Therapeutics Limited. ("Cynata" or the "Company") based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all information necessary to make an investment decision.

This presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in Cynata, nor does it constitute financial product advice or take into account any individual's investment objectives, taxation situation, financial situation or needs. An investor must not act on the basis of any matter contained in this presentation but must make its own assessment of Cynata Therapeutics and conduct its own investigations. Before making an investment decision, investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs, and seek legal, taxation and financial advice appropriate to their jurisdiction and circumstances. Cynata Therapeutics is not licensed to provide financial product advice in respect of its securities or any other financial products. Cooling off rights do not apply to the acquisition of Cynata Therapeutics securities.

Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of Cynata Therapeutics, its officers, directors, employees and agents, nor any other person, accepts any responsibility and liability for the content of this presentation including, without limitation, any liability arising from fault or negligence, for any loss arising from the use of or reliance on any of the information contained in this presentation or otherwise arising in connection with it.

The information presented in this presentation is subject to change without notice and Cynata Therapeutics does not have any responsibility or obligation to inform you of any matter arising or coming to their notice, after the date of this presentation, which may affect any matter referred to in this presentation.

The distribution of this presentation may be restricted by law and you should observe any such restrictions.

Forward looking statements

This presentation contains certain forward looking statements that are based on the Company's management's beliefs, assumptions and expectations and on information currently available to management. Such forward looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results or performance of Cynata to be materially different from the results or performance expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding the Company's present and future business strategies and the political and economic environment in which Cynata will operate in the future, which are subject to change without notice. Past performance is not necessarily a guide to future performance and no representation or warranty is made as to the likelihood of achievement or reasonableness of any forward looking statements or other forecast. To the full extent permitted by law, Cynata and its directors, officers, employees, advisers, agents and intermediaries disclaim any obligation or undertaking to release any updates or revisions to information to reflect any change in any of the information contained in this presentation (including, but not limited to, any assumptions or expectations set out in the presentation).



Our focus

Using our proprietary Cymerus[™] platform technology to develop commercially scalable cellular therapeutic products to treat serious chronic disorders








2019 Highlights: Driving Clinical and Commercial Success



Cynata continues to focus on early commercialisation of Cynata's Cymerus MSC products, and is in active commercial discussions for numerous therapeutic targets


Cynata is executing on a clear scientific and commercial vision and continually assesses pathways to optimise shareholder value






FUJIFILM transaction provides validation of the Cymerus platform and supports the licensing of additional target areas Value inflection point following clear data and first commercial transaction, with Cynata's focus on further license agreements












Dr Kilian Kelly COO

Our patented Cymerus platform enables the production of iPSC-derived cellular therapeutics from **a single adult donor**




Conventional MSC processes



MSCs change when excessively expanded: loss of potency, senescence, decreased efficacy

- limits number of doses that can be produced per donation
- new donors required more frequently
- > more variability

Cymerus iPSC-derived process






Key advantages of the Cymerus process				
CONSISTENCY & SCALABILITY	 ✓ Consistent product quality – single donor overcomes regulatory concerns ✓ Bypasses complex and invasive surgeries with a scalable and cost-effective process ✓ Lower cost of goods on a per cell basis compared to conventional MSC products 			
FEWER CELLS PER PATIENT	 2 infusions per patient in GvHD, compared to 8-12 for bone-marrow derived products ✓ Greater convenience for patients and hospitals ✓ Lower costs incurred by healthcare system 			

Cynata has the only platform in the world able to produce commercial quantities of MSCs from a single source



Over 1,000 clinical trials with MSCs have been initiated¹



Number of MSC clinical trials (cumulative)

Growing body of evidence for the role of MSCs in repair and regeneration



Regenerate diseased and damaged tissue



Modulate the immune system and reduce inflammation



Accelerate recovery from the effects of disease or injury



Approved treatments:

	Cupistem [®] (Anterogen) for Crohn's fistula Queencell [®] (Anterogen) for connective tissue disorders NeuroNata-R [®] (Corestem) for motor neurone disease
	TEMCELL [®] (JCR Pharma) for acute GvHD
۲	Stempeucel [®] (Stempeutics) for CLI due to Buerger's Disease
* * * * * * * * *	Alofisel [®] (TiGenix) for Crohn's fistula

- Conditional approvals have also been granted in Canada and New Zealand for acute GvHD
- First US approval of an MSC-based therapy likely in the near future



Further MSC marketing approvals expected in near future

~30 Phase 3 trials with MSC-based therapies currently active

Indications include:

- Heart failure
- Heart attack ᠰ
- Stroke
- Type II diabetes
- Degenerative disc disease
- Peripheral artery disease 🜙
- Diabetic foot ulcer
- Non-healing fractures
- Chronic GvHD 🤃
- Chronic obstructive pulmonary disease
- Crohn's disease 🔽





Many ongoing Phase 3 trials involve very common conditions, representing **multi-billion** dollar market opportunities



Approvals in any of these indications will significantly **increase Big Pharma's interest** in MSCs



Demand for large quantities of product will focus attention on the **major manufacturing challenges** associated with conventional production methods



Cynata's uniquely scalable and consistent process is ideally placed to solve these manufacturing challenges




Cynata is targeting significant market opportunities

TARGET AREA	TRIAL PHASE	MARKET OPPORTUNITY
Graft vs. Host Disease (GvHD)	Entering Clinical Phase II	US \$0.3bn ¹
Critical limb ischemia (CLI)	Entering Clinical Phase II	US \$1.4bn ²
Osteoarthritis (OA)	Entering Clinical Phase II	US \$11.6 bn ³
Other Asthma, ARDS, Heart Attack, Coronary Artery Disease, Sepsis, Brain Cancer / Glioblastoma, Diabetic Wounds, CRS	Pre-Clinical	

Fujifilm's estimate of the peak annual global sales opportunity
 ClearView's estimate of the peak annual global sales opportunity

Persistence Market Research 2018 research report: "Osteoarthritis Treatment Market: Global Industry Analysis (2012-2016) and Forecast (2017-2025)



CLI is an advanced stage of PAD² caused by a narrowing of the arteries in the limbs¹

PAD affects 3-10% of people aged <70 and 15-20% of people $>70^{1}$

- Risk factors include diabetes, atherosclerosis, smoking, high blood pressure, high cholesterol
- Severely impaired blood flow causes pain, ulceration and gangrene
- >30% of PAD patients have a major artery completely blocked before diagnosis
- CLI often results in amputation; ~25% of CLI patients die within a year of diagnosis


Existing treatment options have very limited success rates

- Lifestyle modification: diet, exercise, smoking cessation .
- **Treating related conditions:** diabetes, high blood pressure, high cholesterol
- **Revascularisation:** e.g. arterial bypass, angioplasty, stent placement



stem cell





Animals treated with Cymerus MSCs experienced **improved blood flow** (p<0.006) and **faster blood flow recovery** (p<0.001) when compared to the control group treated with saline

REVIEW Therapeutic potential for mesenchymal stem cell transplantation in critical limb ischemia Aaron Liew and Timothy O'Brien* Stem cell and progenitor cell therapy in peripheral artery disease A critical appraisal Holger Lawall¹; Peter Bramlage²; Berthold Amann³ ¹SRH-Klinikum Karlsbad-Langensteinbach, Angiology / Diabetology, Karlsbad, Germany, ²Institute for Cardion ³Department of Internal Medicine, Franziskus Krankenhaus, Berlin Vascular Center, Berlin, Germany ular Pharmacology und Epidemiology, Mahlow, Ge **Diabetes Research** and Clinical Practice Comparison of bone marrow mesenchymal stem cells with bone marrow-derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: A double-blind. randomized, controlled trial Debin Lu^a, Bing Chen^{a,*}, Ziwen Liang^a, Wuguan Deng^a, Youzhao Jiang^a, Shufa Li^a, Jing Xu^b, Qinan Wu^a, Zhonghui Zhang^a, Bing Xie^c, Sihao Chen Gupta et al. Journal of Translational Medicine 2013, 11:14 JURNAL OF ://www.translational-medicine.com/content/11/1/14 ANSLATIONAL MEDICINE RESEARCH A double blind randomized placebo controlled phase I/II study assessing the safety and efficacy of allogeneic bone marrow derived mesenchymal stem cell in critical limb ischemia Pawan K Gupta^{1*}, Anoop Chullikana¹, Rajiv Parakh², Sanjay Desai³, Anjan Das¹, Sanjay Gottipamula¹ Sagar Krishnamurthy¹, Naveen Anthony¹, Arun Pherwani⁴ and Anish 5 Majumdar

Combination Stem Cell Therapy for the Treatment of Severe Limb Ischemia: Safety and Efficacy Analysis

Liew and O'Brien Stem Cell Research & Therapy 2012, 3:28

.com/content/3/4/28

Anglology 61(6) 551-556 © The Author(s) 2010 Reprints and permission: sagepub.com/journals/remissions.n Doi: 10.1177/0033197/0364213 http://ang.sagepub.com SAGE

Gabriel P. Lasala, MD, FACC¹, Jose A. Silva, MD, FACC¹, Philip A. Gardner, MD², and Jose J. Minguell, PhD¹

Critical Limb Ischemia | Overview of Cynata-led Phase II program

Estimated market size	230,000 Addressable events per year	~US\$1.4B ¹ Forecast annual global market sales	
Critical LimbIschemia (CLI)	 MSC therapy for effective treatment of CLI patients who are ineligible for revascularization², to promote angiogenesis and reduce inflammation 		
Rationale for selection	 Cymerus preclinical studies were compelling Large body of data on use of MSCs in general in PAD/CLI Development timeline is relatively rapid 		
 Preliminary program design Approximately 90 patients with advanced CLI Clinical centres in UK and Australia Positive meeting with UK MHRA in Feb 2019, clinical submitted 			
image: stateKey□milestones	 Phase II clinical trial in Critical Limb Ischemia expected to commence in early CY2020 		

1.


2.



Estimated market size	30,000,000 People in the USA affected by osteoarthritis	~US\$11.6B ¹ Forecast global market opportunity by 2025	
Osteoarthritis	 Assess the effect of Cymerus MSCs on clinical outcomes and knee joint structures of patients with osteoarthritis of the knee (compared to a placebo) 		
Rationale for selection	 Preclinical research showed MSCs can exert a number of important effects, including: Release of cytokines/growth factors that reduce inflammation and promote tissue repair New blood vessel formation Regeneration of compromised cartilage 		
Preliminary program design	 448-patient trial funded by an NHMRC from participating institutions (no cash Cynata to supply Cymerus MSCs for use commercial rights to the use of Cymeru 	contribution from Cynata) e in the trial ² and will retain full	
i≡Keyi≡milestones	 Phase II clinical trial expected to commence in 1Q CY2020 		



Cynata has a large pipeline of indications with upcoming catalysts



www.cynata.com



Thank you for your attention

Cynata Therapeutics Limited

Level 3 62 Lygon Street Carlton Victoria 3053 Australia

Contact details:



ross.macdonald@cynata.com



www.cynata.com

